
EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013


Business today/YES bank Excellence Awards-2013

Eris Lifesciences Ltd.

Date: 24th July, 2019

To **The Department of Corporate Services** **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	**To** **National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	**Symbol: ERIS**

SUBJECT: INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

This is further to our letter dated 20th July, 2019 intimating about the date of the Board of Directors Meeting to inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30th June, 2019.

We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Monday, 29th July, 2019. The detail of the said call is attached herewith and also available on Company's website.

Thanking you.

For Eris Lifesciences Limited



Milind Talegaonkar
Company Secretary and Compliance Officer
Membership No.: A26493

Encl.:a/a

Axis House, C-2, Wadia International Centre, P.B Marg. Worli, Mumbai 400 025 (India)

Eris Lifesciences Ltd.

Q1FY20 Earnings Call on 29th July 2019
hosted by Axis Capital Limited

We are pleased to host, on behalf of Eris Lifesciences Ltd., a **conference call for analysts and investors on Monday, 29th July 2019** following the announcement of financial results for the quarter ended June 2019.

The company will be represented by the senior management team, and will initiate the call with a brief discussion on the earnings performance followed by an interactive Question & Answer session.

Details of the conference call are:

Date	:	Monday, 29th July 2019
Time	:	**11:00 AM IST | 01:30 PM HK/SG | 06:30 AM UK**
Call Leader	:	Mr. Prakash Agarwal, Axis Capital Limited

Country		Dial in numbers
Primary number	:	+91 22 6280 1145 +91 22 7115 8046
India Local	:	+91 7045671221 (Available all over India)
International Dial In		
- Hong Kong	:	800 964 448
- Singapore	:	800 101 2045
- U K	:	0 808 101 1573
- USA	:	1 866 746 2133

Copy this URL in your browser: https://services.choruscall.in/ChorusCall/login_en

For further information please contact

Prakash Agarwal
Dy Head - Research | Executive Director – Pharmaceuticals
Axis Capital Limited
Direct: +91 22 4325 1145
Mobile: +91 9820534334
Email: prakash.agarwal@axiscap.in

Dhagash Vora
AVP – Pharmaceuticals
Axis Capital Limited
Direct: +91 22 4325 1129
Mobile: +91 9892361383
Email: dhagash.vora@axiscap.in